GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1) adjuvanted vaccine Pandemrix™ for protection against pandemic H1N1 2009 influenza. “Following the Commission’s approval we expect to commence shipments of Pandemrix to European governments from next week,” said Jean Stéphenne, President GlaxoSmithKline Biologicals.
